Sugi Predict

Sugi Predict / Compounds / SCHEMBL536056

SCHEMBL536056

SCHEMBL536056

CC(C)(C)OC(=O)Nc1ccncc1Cl

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NOD2 Q9HC29 1/20 0.50
▸ NAMPT P43490 1/20 0.47
▸ CYP17A1 P05093 3/20 0.46
▸ GALR3 O60755 1/20 0.46
▸ NR2F2 P24468 1/20 0.46
▸ ATR Q13535 1/20 0.46
▸ PDE4A P27815 4/20 0.44
▸ PDE4B Q07343 4/20 0.44
▸ PDE4C Q08493 4/20 0.44
▸ PDE4D Q08499 4/20 0.44
▸ RAB9A P51151 1/20 0.43
▸ AAK1 Q2M2I8 1/20 0.42
▸ METAP1 P53582 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31707395 1.00 NOD2 (0.50) NOD2NAMPTCYP17A1GALR3NR2F2
SCHEMBL3229288 0.88 NAMPT (0.47) NAMPTCYP17A1ATRRAB9AAAK1
SCHEMBL18522430 0.86 NAMPT (0.50) NAMPTCYP17A1ATRRAB9AMETAP1
SCHEMBL2107971 0.83 NAMPT (0.48) NAMPTCYP17A1ATRRAB9AMETAP1
SCHEMBL3666785 0.83 NAMPT (0.48) NAMPTCYP17A1ATRRAB9AMETAP1
SCHEMBL15039524 0.82 CYP17A1 (0.55) NAMPTCYP17A1ATRRAB9AAAK1
SCHEMBL16307603 0.82 CYP17A1 (0.55) NAMPTCYP17A1ATRRAB9AAAK1
SCHEMBL4827917 0.82 NAMPT (0.47) NAMPTCYP17A1ATRRAB9AMETAP1
SCHEMBL5746021 0.82 NAMPT (0.47) NAMPTCYP17A1RAB9AAAK1
SCHEMBL741240 0.82 NAMPT (0.47) NAMPTCYP17A1ATRRAB9AMETAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049080-A1 WILD TYPE KIT INHIBITORS BLUEPRINT MEDICINES CORP (US) 2026-02-19 — — US disclosed
US-12448379-B2 Wild type kit inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2025-10-21 — — US disclosed
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 — — US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 — — WO disclosed
US-20240262826-A1 WILD TYPE KIT INHIBITORS BLUEPRINT MEDICINES CORPORATION 2024-08-08 — — US disclosed
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 — — WO disclosed
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PROMIDIS S.R.L. (IT) 2024-04-04 — — US disclosed
WO-2022167682-A1 AZABICYCLIC SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-08-11 — — WO disclosed
EP-3233866-B1 PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS Bayer Pharma AG (DE) 2021-04-21 — — EP disclosed
EP-3233866-B1 PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS Bayer Pharma AG (DE) 2021-04-21 — — EP disclosed
EP-2144898-B1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL CO (JP) 2012-02-08 — — EP disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 — — US disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 — — US disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 — — US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US disclosed
EP-2144898-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-20 — — EP disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 — — EP disclosed
WO-2008130021-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-10-30 — — WO disclosed
WO-2008130021-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-10-30 — — WO disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PTPN22, PTPN2, PTPN5 NOD2 2025/4885NAMPT 1554/4885CYP17A1 2882/4885
US-20260049080-A1 WILD TYPE KIT INHIBITORS KIT, CSNK1A1, CSNK1A1L NOD2 3741/4885NAMPT 4633/4885CYP17A1 723/4885
US-12448379-B2 Wild type kit inhibitors KIT, TNK1, TNNI3K NOD2 3744/4885NAMPT 2003/4885CYP17A1 1372/4885
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 NOD2 845/4885NAMPT 358/4885CYP17A1 1188/4885
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR NOD2 1573/4885NAMPT 1500/4885CYP17A1 2755/4885
US-20240262826-A1 WILD TYPE KIT INHIBITORS KIT, TNK1, TNNI3K NOD2 3744/4885NAMPT 2003/4885CYP17A1 1372/4885
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME ACHE, CAT, DNPH1 NOD2 1879/4885NAMPT 270/4885CYP17A1 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.